Compare · CLDX vs IMDX
CLDX vs IMDX
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Insight Molecular Diagnostics Inc. (IMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and IMDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- CLDX is the larger of the two at $2.62B, about 15.0x IMDX ($174.4M).
- Over the past year, CLDX is up 64.0% and IMDX is up 42.9% - CLDX leads by 21.1 points.
- IMDX has been more active in the news (8 items in the past 4 weeks vs 3 for CLDX).
- CLDX has more recent analyst coverage (21 ratings vs 0 for IMDX).
- Company
- Celldex Therapeutics Inc.
- Insight Molecular Diagnostics Inc.
- Price
- $33.39+2.96%
- $5.35-1.83%
- Market cap
- $2.62B
- $174.4M
- 1M return
- +8.01%
- -13.50%
- 1Y return
- +63.96%
- +42.86%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 21
- 0
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest CLDX
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
- Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
- Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
- SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.
- SEC Form 10-Q filed by Celldex Therapeutics Inc.
- Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celldex Reports First Quarter Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- SEC Form DEF 14A filed by Celldex Therapeutics Inc.
- Celldex Therapeutics upgraded by Barclays with a new price target
Latest IMDX
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
- Director Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)
- IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
- iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits